CoChat

Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer

Open access
Yang, Jian, Gong, Yuhua, Lam, Vincent K., Shi, Yan, Guan, Yanfang, Zhang, Yanyan, Ji, Liyan, Chen, Yongsheng, Zhao, Yongliang, Qian, Feng, Chen, Jun, Li, Pingang, Zhang, Fan, Wang, Jiayin, Zhang, Xuanping, Yang, Ling, Kopetz, Scott, Futreal, P. Andrew, Zhang, Jianjun, Yi, Xin, Xia, Xuefeng, Yu, Peiwu · 2020 · Cell Death & Disease
Cited by 200

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Identifying locoregional gastric cancer patients who are at high risk for relapse after resection could facilitate early intervention. By detecting molecular residual disease (MRD), circulating tumor DNA (ctDNA) has been shown to predict post-operative relapse in several cancers. Here, we aim to evaluate MRD detection by ctDNA and its association with clinical outcome in resected gastric cancer. This prospective cohort study enrolled 46 patients with stage I–III gastric cancer that underwent resection with curative intent. Sixty resected tumor samples and 296 plasma samples were obtained for targeted deep sequencing and longitudinal ctDNA profiling. ctDNA detection was correlated with clinicopathologic features and post-operative disease-free (DFS) and overall survival (OS). ctDNA was detected in 45% of treatment-naïve plasma samples. Primary tumor extent (T stage) was independently associated with pre-operative ctDNA positivity (p = 0.006). All patients with detectable ctDNA in the immediate post-operative period eventually experienced recurrence. ctDNA positivity at any time during longitudinal post-operative follow-up was associated with worse DFS and OS (HR = 14.78, 95%CI, 7.991–61.29, p < 0.0001 and HR = 7.664, 95% CI, 2.916–21.06, p = 0.002, respectively), and preceded radiographic recurrence by a median of 6 months. In locoregional gastric cancer patients treated with curative intent, these results indicate that ctDNA-detected MRD identifies patients at high risk for recurrence and can facilitate novel treatment intensification studies in the adjuvant setting to improve survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-2531-z

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 200

Metadata

Authors
Yang, J., Gong, Y., Lam, V. K., Shi, Y., Guan, Y., Zhang, Y., Ji, L., Chen, Y., Zhao, Y., Qian, F., Chen, J., Li, P., Zhang, F., Wang, J., Zhang, X., Yang, L., Kopetz, S., Futreal, P. A., Zhang, J., Yi, X., Xia, X., & Yu, P.
Venue
Cell Death & Disease
Published
2020-05-11
Volume
11
Issue
5
Pages
346-346
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3021453484
Cited by
200
References
5
FWCI
7.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. https://app.cochat.ai/papers/10.1038/s41419-020-2531-z
The paper
Yang, J., Gong, Y., Lam, V. K., Shi, Y., Guan, Y., Zhang, Y., Ji, L., Chen, Y., Zhao, Y., Qian, F., Chen, J., Li, P., Zhang, F., Wang, J., Zhang, X., Yang, L., Kopetz, S., Futreal, P. A., Zhang, J., . . . Yu, P. (2020). Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death & Disease. https://doi.org/10.1038/s41419-020-2531-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.